FL-NCIPHER-SECURITY
17.9.2019 09:03:05 CEST | Business Wire | Press release
nCipher Security, an Entrust Datacard company , announces nShield as a Service , a cloud-based hardware security module (HSM) service that allows organizations to protect sensitive data and applications and helps meet compliance mandates – simply and efficiently, using on-demand cryptography.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190917005391/en/
“Organizations embracing cloud-first strategies require cloud-first encryption,” said Peter Galvin, vice president of strategy, nCipher Security. “This means remote, automated management at scale, and flexible access control both in the cloud and onsite. nShield as a Service makes it easy to adopt a secure, multi-cloud encryption strategy using the same nShield HSMs organizations deploy onsite today.”
nShield as a Service is ideal for cloud-first strategies, selective cloud migration, or adding HSM capacity to handle workload spikes. The customer experience is consistent and familiar – users interact with the cloud-based nShield® HSMs in the same way as with nShield appliances in their own data centers. And customers utilizing nCipher’s unique secure execution environment to run sensitive application code within a secure FIPS-validated boundary now have that same opportunity using cloud-based as well as on premises HSMs.
Using nShield as a Service, customers can:
- implement Bring Your Own Key and Host Your Own Key solutions with a trusted third party service
- maintain full control over key material and maintain separation of data from the encryption keys
- extend cloud-based cryptography and key management across multiple clouds
- implement secure code execution for cloud-based workloads
- integrate with third party applications in the cloud
“The nShield as a Service launch highlights the synergies we’ve gained since becoming an Entrust Datacard company in June,” Galvin said. “We were able to accelerate and enhance nShield as a Service by combining our HSM and cryptography expertise with Entrust Datacard’s experience in data centers, cloud services and HSM operations. The result is a powerful HSM as a service solution that complements the company’s cloud-based PKI and IoT security solutions.”
“Encryption is a powerful tool,” said Robert Westervelt, Research Director, Security Products, IDC. “Delivering it easily across distributed infrastructure can be very effective in protecting data and applications against cyberattacks. Solutions such as nShield as a Service allow even the largest organizations to secure their public cloud workloads with all the conveniences of software-as-a-service offerings. Now, there are no excuses for not using encryption in the cloud.”
How nShield as a Service works
nShield as a Service uses nShield HSMs to generate, access and protect cryptographic key material separately from sensitive data. All nShield HSMs are managed through nCipher’s unique Security World key management architecture that spans cloud-based and on premises HSMs. This lets customers efficiently scale HSM operations while retaining control of their key material, even if they change their cloud service provider.
Organizations can utilize nShield as a Service to supplement or replace on premises HSMs, while keeping the benefits of HSM ownership. The subscription model lets enterprises budget predictably, manage capacity, reduce data center footprint and decrease time spent on routine maintenance and monitoring.
Customers seeking cloud-first solutions can work with market-leading cybersecurity and infrastructure vendors in nCipher’s nFinity Strategic Technology Partner program , including F5, IBM, Micro Focus Voltage, Red Hat and Venafi (see quote sheet below). Applications include SSL/TLS, code signing, data and database encryption and more.
nCipher Security nFinity Strategic Technology Partners talk about nShield as a Service:
F5
“F5 has deep experience in application delivery and security services and helps customers protect their critical applications, ensuring they are safe, secure, and available. The launch of nShield as a Service from nCipher Security gives F5 customers enhanced security choices with the ability to achieve data sovereignty on a subscription-based model. Shifting security from a capital to an operational expenditure enables greater flexibility and cost-effectiveness for organizations,” said John Morgan, VP & GM of Security at F5 Networks.
Rick Robinson, WW Offering Manager, Encryption and Key Management, IBM Security:
“As enterprises increasingly migrate business processes to the cloud, security continues to be a major concern. Ensuring that critical applications and their underpinning cryptographic keys can be protected and managed throughout their lifecycle is vital. The launch of nShield as a Service from nCipher Security gives our joint customers greater choice and the ability to have subscription-based data sovereignty,” said Rick Robinson, WW Offering Manager, Encryption and Key Management, IBM Security.
Micro Focus Voltage
“Data is one of the most abundant and valuable assets for an organization today,” said Reiner Kappenberger, Director Product Management, Voltage Data Security at Micro Focus. “However, without reliable ways to protect data at rest, in motion, and in use, these very assets can become liabilities. As Voltage SecureData customers increasingly migrate storage and workloads to cloud-based environments, they are looking to establish an HSM-based root of trust in the cloud that can maintain the highly available, highly performant data-centric solution they currently enjoy. nShield as a Service from nCipher Security, through its support of Voltage SecureData’s innovative Stateless Key Management, enables Micro Focus to offer its customers continuing relief from the burden of traditional key management in both hybrid and zero data center cloud deployments.”
Red Hat
“As a long-standing nCipher Security nFinity technology partner and the world’s leading provider of open source solutions, Red Hat is committed to providing customers with more choices to enhance. nShield as a Service from nCipher will offer expanded choice to our customers in how they pursue IT security to better protect the underlying cryptographic keys that help to secure Red Hat Certificate System and Red Hat OpenStack Platform deployments across the hybrid cloud,” said Keith Basil, Senior Principal Product Manager at Red Hat.
Venafi
“As the leader in machine identity protection, Venafi welcomes the launch of the new nShield as a Service capability from nCipher Security,” said Kevin Bocek, VP Security Strategy and Threat Intelligence at Venafi. “With the number of machines growing exponentially, and the definition of machines expanding to include everything from containers in Kubernetes clusters running in cloud to embedded IoT devices that will be deployed for the next 20 years, securing machine identities is critical for every business and government. The new nShield as a Service delivers the same robust root of trust that customers have come to depend on with on-premises nShield HSMs, adding a subscription-based security alternative that is easy to use, flexible, and cost-effective for organizations no matter their size. This is an exciting development that will help fast DevOps and security teams move at cloud speed to secure TLS and code signing keys certificates.”
About nCipher Security
nCipher Security, an Entrust Datacard company , is a leader in the general-purpose hardware security module (HSM) market, empowering world-leading organizations by delivering trust, integrity and control to their business-critical information and applications. Today’s fast-moving digital environment enhances customer satisfaction, gives competitive advantage and improves operational efficiency – it also multiplies the security risks. Our cryptographic solutions secure emerging technologies such as cloud, IoT, blockchain, and digital payments and help meet new compliance mandates. We do this using our same proven technology that global organizations depend on today to protect against threats to their sensitive data, network communications and enterprise infrastructure. We deliver trust for your business-critical applications, ensure the integrity of your data and put you in complete control – today, tomorrow, always. www.ncipher.com
Follow us on LinkedIn , Twitter , Facebook and Instagram – search nCipherSecurity.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190917005391/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
